多西他赛与吉非替尼序贯应用对人肺腺癌细胞SPC-A1生长及信号蛋白的影响

背景与目的已经证明:化疗联合表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor recep-tor-tyrosine kinase inhibitors,EGFR-TKIs)与单独化疗比较治疗晚期非小细胞肺癌并不能增加疗效,但机制尚未完全明了.本研究通过观察多西他赛与吉非替尼不同时序应用对...

Sequence-dependent Effect of Docetaxel with Gefitinib on the Proliferation and Signal Protein Expression of Human Lung Adenocarcinoma Cell SPC-A1

Background and objective It has been proven that chemotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) could not increase response for advanced non-small cell lung cancer(NSCLC) ,but its cellular mechanism was not well known. The aim of this study is to assess the effects of sequential administration of docetaxel and gefitinib on the cell proliferation and signal pathway of lung adenocarcinoma cell SPC-A1 and its cellular mechanism. Methods The mutation of EGFR and K-ras gene were examined by qPCR-HRM. MTT assay was used to measure the cell proliferation. The expression and phosphorylation of EGFR,ERK,AKT and IGF-1R were determined by Western blot. Results No EGFR or K-ras gene mutation was found in SPC-A1 cells. Compared with docetaxel or gefitinib alone,no synergistic effects on the cell proliferation were observed in cells treated with docetaxel and gefitinib concomitantly or gefitinib followed by docetaxel. However,sequential administration of gefitinib following docetaxel could remarkably increase the inhibition of docetaxel on cell proliferation. Docetaxel increased,and gefitinib decreased,the phosphorylation of EGFR and ERK respectively. The suppression of pEGFR and pERK induced by gefitinib could not be activated by docetaxel,whether simultaneously or subsequently. No significant effects on the expression of AKT and p-AKT were found when docetaxel and gefitinib were administered simultaneously or sequentially. Docetaxel decreased the expression of IGF-1R. Conclusion The phosphorylation of both EGFR and ERK,not the phosphorylation of AKT or the expression of IGFR,may contribute to the synergistic effects of EFGR-TKI following chemotherapy on the cell proliferation of NSCLC.